

Medicine Research Career Development Program (grant no. 5K12HL109005-03). H.A.S. is supported in part by grants from the National Institute of Allergy and Infectious Diseases (grant nos. AI44236 and AI066738) and the National Center for Advancing Translation Sciences (grant no. RR026134), National Institutes of Health. Disclosure of potential conflicts of interest: H. A. Sampson and J. D. Kattan received research support from the National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest.

REFERENCES

1. Sicherer SH, Wood RA, Sicherer SH, Abramson S, Chipps BE, Fleisher T, et al. Allergy testing in childhood: using allergen-specific IgE tests. *Pediatrics* 2011. Available from: <http://pediatrics.aappublications.org/content/early/2011/12/21/peds.2011-2382>. Accessed March 1, 2014.
2. Bernstein IL, Li JT, Bernstein DI, Hamilton R, Spector SL, Tan R, et al. Allergy diagnostic testing: an updated practice parameter. *Ann Allergy Asthma Immunol* 2008;100:S1-148.
3. Twardosz-Kropfmüller A, Singh MB, Niederberger V, Horak F, Kraft D, Spitzauer S, et al. Association of allergic patients' phenotypes with IgE reactivity to recombinant pollen marker allergens. *Allergy* 2010;65:296-303.
4. Ott H, Baron JM, Heise R, Ockelburg C, Stanzel S, Merk H-F, et al. Clinical usefulness of microarray-based IgE detection in children with suspected food allergy. *Allergy* 2008;63:1521-8.
5. Radauer C, Nandy A, Ferreira F, Goodman RE, Larsen JN, Lidholm J, et al. Update of the WHO/IUIS Allergen Nomenclature Database based on analysis of allergen sequences. *Allergy* 2014;69:413-9.
6. Eggleston PA, Rosenstreich D, Lynn H, Gergen P, Baker D, Kattan M, et al. Relationship of indoor allergen exposure to skin test sensitivity in inner-city children with asthma. *J Allergy Clin Immunol* 1998;102:563-70.
7. Stoltz DJ, Jackson DJ, Evans MD, Gangnon RE, Tisler CJ, Gern JE, et al. Specific patterns of allergic sensitization in early childhood and asthma & rhinitis risk. *Clin Exp Allergy* 2013;43:233-41.
8. Brockow I, Zutavern A, Hoffmann U, Grübl A, von Berg A, Koletzko S, et al. Early allergic sensitizations and their relevance to atopic diseases in children aged 6 years: results of the GINI study. *J Investig Allergol Clin Immunol* 2009;19:180-7.
9. Konradsen JR, Nordlund B, Onell A, Borres MP, Grönlund H, Hedlin G. Severe childhood asthma and allergy to furry animals: refined assessment using molecular-based allergy diagnostics. *Pediatr Allergy Immunol* 2014;25:187-92.

Available online November 12, 2015.
<http://dx.doi.org/10.1016/j.jaci.2015.09.035>

Filaggrin genotype does not determine the skin's threshold to UV-induced erythema



To the Editor:

Profilaggrin and filaggrin play multiple roles in the formation and function of the epidermal barrier, contributing to protection against dehydration, mechanical stress, infection, and, it has been proposed, photodamage.¹ Loss-of-function mutations in the gene encoding filaggrin (*FLG*) represent the strongest and most significant genetic risk factor for atopic dermatitis (AD) identified to date.¹ Proteolysis of filaggrin releases histidine and other amino acids into the stratum corneum. Histidine is converted by the enzyme histidase (histidine ammonia-lyase) to *trans*-urocanic acid (*trans*-UCA), which can then undergo photoisomerization on absorption of UVB to produce *cis*-UCA (see Fig E1 in this article's Online Repository at www.jacionline.org). There is experimental evidence to suggest that *cis*-UCA has immunomodulatory and photoprotective effects.

TABLE I. Demographic data and *FLG* genotype results for 71 volunteers with clinically normal skin

Sex	43 male/28 female
Age (y), range (median)	22-70 (41)
<i>FLG</i> wild-type subjects (no.)	61
<i>FLG</i> heterozygotes (no.)	10
Total (no.)	71

Volunteers were screened for the 6 most prevalent *FLG* loss-of-function mutations in the population. Five subjects were heterozygous for R501X, 3 were heterozygous for 2282del4, 1 was heterozygous for R2447X, and 1 was heterozygous for S3247X. No 3673delC or 3702delG mutations were detected, and there were no homozygotes or compound heterozygotes. Fitzpatrick skin phototype was recorded for 45 of 71 subjects, and there was no significant difference ($P = .14$, χ^2 test) in skin phototypes between the genotype subgroups.

The local and systemic immunosuppressive effects of *cis*-UCA were initially demonstrated in murine models, and more recently, histidinemic mice deficient in cutaneous UCA because of a mutation in *Hal*, the gene encoding histidase, have been reported to show increased propensity to UVB-induced DNA damage.² Mice deficient in caspase-14 (an enzyme in the profilaggrin-filaggrin proteolytic pathway) show accumulation of cyclobutane pyrimidine dimers in response to UVB radiation and increased apoptosis in the epidermis, indicating a role for caspase-14 in UVB scavenging within the stratum corneum.³ The immunosuppressive effects of *cis*-UCA have been demonstrated in human keratinocytes and leukocytes *in vitro*; knockdown of *FLG* in organotypic culture results in increased susceptibility of keratinocytes to UV-induced apoptosis.⁴ Loss-of-function mutations and copy number variation in *FLG* are known to result in lower levels of filaggrin breakdown products, including UCA, in human stratum corneum. Therefore it has been postulated that *FLG* genotype might in part determine the photoprotective capacity of human skin (see Fig E1),¹ but experimental evidence *in vivo* is lacking.

We aimed to test the hypothesis that filaggrin deficiency resulting from loss-of-function mutations in *FLG* is associated with increased erythema sensitivity to UV radiation. Cutaneous response to UV radiation was assessed by using the minimal erythema dose (MED; the lowest dose of UV causing just perceptible skin redness) as a quantifiable surrogate end point for cutaneous damage. We used detailed monochromator phototesting of 71 adult volunteers of white European ethnicity with clinically normal skin; the demographic characteristics are summarized in Table I. A calculation performed before this study commenced indicated that 7 or 8 *FLG* mutation carriers within a total study size of 70 to 80 subjects would provide sufficient statistical power to detect a 1.8-fold difference in MED. This sample size estimation was based on known variability in MEDs from previous studies and assuming comparisons of arithmetic means of log-transformed data (therefore able to back-transform differences into fold differences). Details of the power calculation are shown in the Methods section in this article's Online Repository at www.jacionline.org.

This work was approved by the East of Scotland Research Ethics Committee (reference 14/ES/0030), and the study was conducted in accordance with the Declaration of Helsinki.

Participants were screened for the 6 most prevalent loss-of-function mutations in *FLG* in the white European population (R501X, 2282del4, R2447X, S3247X, 3673delC, and 3702delG) by using published methodology.⁵ Ten (14%) of 71




FIG 1. Box plots showing monochromator phototesting MED results in healthy volunteers of different *FLG* genotypes. The findings for 5 distinct wavebands are shown. Results for the 400 ± 30 and 430 ± 30 nm wavebands showed no difference between *FLG* wild-type and heterozygotes (see Table E1); these data are not displayed because the median MEDs and ranges are not quantifiable. Boxes indicate interquartile ranges, and the bar within each box marks the median result. The difference in median MEDs (and 95% CIs) are shown above each plot. All values are in millijoules per square centimeter. Median MEDs were compared by using the Mann-Whitney *U* test. There were 61 *FLG* wild-type subjects and 10 *FLG* heterozygous subjects tested in each group, with the exception of the 295 nm and 300 nm wavebands, in which data were obtained on 53 *FLG* wild-type subjects and 8 *FLG* heterozygous subjects.

were found to be heterozygous for a loss-of-function mutation in *FLG* (Table 1). Fitzpatrick sun-reactive skin phototype was recorded for 45 of 71 subjects, and no difference was detected ($P = .14$, χ^2 test) in skin phototypes between the genotype subgroups.

Up to 7 separate wavebands from 295 to 430 nm, representing a spectrum from UVB to UVA and visible light, were tested on the 71 subjects. A detailed description of phototesting methods is given in the Methods section in this article's Online Repository. Subjects were grouped according to *FLG* genotype, and MEDs were compared by using nonparametric rank-based methods (because some MED values were greater than or less than test dose ranges) with the Mann-Whitney *U* test (see the Methods section in this article's Online Repository) to derive CIs for differences in median MEDs (see Table E1 in this article's Online Repository at www.jacionline.org). We detected no significant differences in MEDs (defined as $P \leq .05$) between the *FLG*

wild-type and *FLG* heterozygous groups at any of the wavebands tested (Fig 1 and see Table E1). The CIs for differences were sufficiently narrow to make any large differences in MEDs between the genotype groups unlikely.

It has previously been reported that AD might be associated with photosensitivity,⁶ a lower threshold to UVB-induced erythema,⁷ or both. Some epidemiologic data also suggest a higher incidence of multiple nonmelanoma skin cancers in subjects with a history of AD.⁸ Loss-of-function mutations in *FLG* are strongly associated with AD, and there is widespread downregulation of filaggrin expression in the skin of patients with atopic eczema, which has been demonstrated at the transcriptome level by means of direct RNA sequencing,⁹ and in the breakdown products of filaggrin in the stratum corneum, which was quantified by means of HPLC.¹⁰ A partial reduction in expression of filaggrin might result from the effect of circulating inflammatory cytokines, whereas a more profound deficiency results from

loss-of-function mutations in *FLG* leading to near-complete absence of profilaggrin in the homozygous or compound heterozygous state. Therefore it can be hypothesized that filaggrin deficiency contributes to the observed photosensitivity and/or reduced threshold to UVB-induced erythema in patients with AD. We have performed a detailed analysis of cutaneous photoresponse in clinically normal skin to avoid the confounding effects of atopic inflammation. Our findings have excluded a large effect of *FLG* genotype on photosensitivity (≥ 1.8 -fold difference in MED) at any of the wavebands tested. In addition, the results of our monochromator phototesting did not indicate a differential erythema sensitivity within the wavelengths representing UVB, as would be predicted from the known absorption spectrum of UCA.

One limitation of our study is that the healthy volunteers did not include any subjects with ichthyosis vulgaris, and therefore we have not excluded the possibility that *FLG* homozygous (or compound heterozygous) subjects might show greater erythema sensitivity than wild-type subjects. However, *FLG*-null heterozygosity has a significant effect on filaggrin expression *in vivo*,^{9,10} and therefore we would expect an effect to be observed in *FLG* heterozygotes if this was substantial.

The fact that observations of UVB-induced damage in murine and *in vitro* models have not been supported by clinical data suggest that different mechanisms lead to cutaneous erythema *in vivo* than the markers of UV damage studied *in vitro* and in mice. For example, apoptosis is known to occur within areas of skin damaged by UV exposure, and this is associated with cutaneous erythema, but the relationship is nonlinear. Furthermore, the photoprotective effect of the *FLG* wild-type genotype might be attributable to a mechanical filtering of UV radiation by the stratum corneum rather than by chemical photoimmunosuppression.

In conclusion, our *FLG* genotype-stratified analysis of responses to UV and visible radiation in clinically normal skin does not support the hypothesis that the breakdown products of filaggrin play a major role in the sensitivity of human skin to UV-induced erythema. This has relevance to the ongoing search for predictors of patient response in phototherapy for AD and for the development of personalized medicine.

We thank the patients and volunteers who participated in this study and Lynn Fullerton, who provided technical support in the photobiology investigations. We are very grateful to Professors James Ferguson and Peter Farr for their expert advice in the design and conduct of these studies.

Deborah Forbes^a

Leona Johnston, MSc^b

June Gardner, RGN^b

Stephanie F. MacCallum, MSc^c

Linda E. Campbell, BSc^c

Albena T. Dinkova-Kostova, PhD^d

W. H. Irwin McLean, DSc^e

Sally H. Ibbotson, MD^b

Robert S. Dawe, MD^b

Sara J. Brown, MD^e

From ^aNinewells Hospital and Medical School, Dundee, United Kingdom; ^bthe Photobiology Unit, Dermatology Department, and ^dthe Division of Cancer Research, Medical Research Institute, Jacqui Wood Cancer Centre, University of Dundee, Ninewells Hospital and Medical School, Dundee, United Kingdom; ^cDermatology and Genetic Medicine, Division of Molecular Medicine, College of Life Sciences and College of Medicine, Dentistry and Nursing, University of Dundee, Dundee, United Kingdom; and ^eDermatology and Genetic Medicine, Medical Research Institute, College of Medicine, Dentistry and Nursing, Ninewells Hospital and Medical School, Dundee, United Kingdom. E-mail: s.j.brown@dundee.ac.uk.

D.F. was supported by the Muir Russell studentship. S.J.B. holds a Wellcome Trust Intermediate Fellowship (086398/Z/08/Z) and is supported by the Manknell Charitable Trust and the Tayside Dermatology Research Fund. The Centre for Dermatology and Genetic Medicine, University of Dundee, is funded by a Wellcome Trust Strategic Award (098439/Z/12/Z; to W.H.I.M.).

Disclosure of potential conflict of interest: D. Forbes has received research support in the form of a summer studentship from the Dundee Academic Clinical Track and has received travel support from DCAT Travel Bursary and the Tayside Dermatological Research Charity. W. H. I. McLean has received research support from the Wellcome Trust. S. J. Brown has received research support in the form of Fellowships from the Wellcome Trust and research grants from the Manknell Charitable Trust and the Tayside Dermatology Research Fund and has received speaker's honorarium from the American Academy of Allergy, Asthma & Immunology. The rest of the authors declare that they have no relevant conflicts of interest.

REFERENCES

- Sandilands A, Sutherland C, Irvine A, McLean W. Filaggrin in the frontline: role in skin barrier function and disease. *J Cell Sci* 2009;122:1285-94.
- Barresi C, Stremnitzer C, Mlitz V, Kezic S, Kammeyer A, Ghannadan M, et al. Increased sensitivity of histidinemic mice to UVB radiation suggests a crucial role of endogenous urocanic acid in photoprotection. *J Invest Dermatol* 2011;131:188-94.
- Denecker G, Hoste E, Gilbert B, Hocheppied T, Ovaere P, Lippens S, et al. Caspase-14 protects against epidermal UVB photodamage and water loss. *Nat Cell Biol* 2007;9:666-74.
- Mildner M, Jin J, Eckhart L, Kezic S, Gruber F, Barresi C, et al. Knockdown of filaggrin impairs diffusion barrier function and increases UV sensitivity in a human skin model. *J Invest Dermatol* 2010;130:2286-94.
- Sandilands A, Terron-Kwiatkowski A, Hull P, O'Regan G, Clayton T, Watson R, et al. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. *Nat Genet* 2007;39:650-4.
- ten Berge O, van Weelden H, Bruijnzeel-Koomen CA, de Bruin-Weller MS, Sigurdsson V. Throwing a light on photosensitivity in atopic dermatitis: a retrospective study. *Am J Clin Dermatol* 2009;10:119-23.
- Tajima T, Ibe M, Matsushita T, Kamide R. A variety of skin responses to ultraviolet irradiation in patients with atopic dermatitis. *J Dermatol Sci* 1998;17:101-7.
- Dyer RK, Weinstock MA, Cohen TS, Rizzo AE, Bingham SF, Group VT. Predictors of basal cell carcinoma in high-risk patients in the VATTC (VA Topical Tretinoin Chemoprevention) trial. *J Invest Dermatol* 2012;132:2544-51.
- Cole C, Kroboth K, Schurch NJ, Sandilands A, Sherstnev A, O'Regan GM, et al. Filaggrin-stratified transcriptomic analysis of pediatric skin identifies mechanistic pathways in patients with atopic dermatitis. *J Allergy Clin Immunol* 2014;134:82-91.
- Kezic S, O'Regan GM, Yau N, Sandilands A, Chen H, Campbell LE, et al. Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severity. *Allergy* 2011;66:934-40.

Available online January 29, 2016.

<http://dx.doi.org/10.1016/j.jaci.2015.11.022>

Epidermal thymic stromal lymphopoietin predicts the development of atopic dermatitis during infancy



To the Editor:

To establish a primary prevention strategy for atopic dermatitis (AD), it is important to identify biomarkers that can predict the occurrence of AD. This study aimed to evaluate the expression level of epidermal proteins by using a tape stripping method to determine whether these proteins can be used as biomarkers predictive of AD development in infants.

In this prospective birth cohort study, we followed 75 infants in a risk group and 12 in a control group for 2 years (Fig 1). The control group consisted of infants with both parents who had neither allergy nor immediate skin test reactivity to 8 common inhalant allergens (*Dermatophagoides pteronyssinus*, *Dermatophagoides farinae*, tree pollen mixture I & II, weed pollen mixture, grass pollen mixture, cat, and cockroach). The risk group was defined

METHODS

Assessment of MEDs of different wavebands in healthy volunteers

Healthy adults with clinically normal skin of phototypes I to III^{E1} who had previously participated in research studies within the National Photobiology Unit (Dundee, Scotland, United Kingdom) were invited to participate in this study. Exclusion criteria were history of skin allergy, eczema/AD, psoriasis or polymorphic light eruption, immunosuppression caused by medications or disease, photosensitizing medication, and a holiday abroad or sunbed use within the preceding 4 weeks. A total of 71 subjects provided written informed consent and a saliva sample for DNA extraction. Emollient application to skin test sites was not allowed within the 48 hours before phototesting.

Detailed phototesting was undertaken by using an irradiation monochromator, which is a diffraction grating device with a 1.6-kW or 450-W xenon arc lamp.^{E2,E3} This instrument allows irradiation of small areas of the skin over a range of wavebands, which are included in the solar spectrum (UVB to UVA/visible). Monochromator phototesting was performed as follows. On day 1, approximately 1-cm² areas of the skin on the volunteer's back were exposed to UV and visible light according to a standardized procedure established in the National Photobiology Unit. A range of doses of UV and visible light at specific narrow wavebands was used for all subjects centered on (with half-maximum bandwidth) 295 ± 5, 300 ± 5, 305 ± 5, 335 ± 30, 365 ± 30, 400 ± 30, and 430 ± 30 nm.

The MED, which was defined as the minimum dose producing just perceptible erythema for each waveband tested, was determined 24 hours after irradiation. The irradiation procedure was repeated on day 2 on a separate area of back skin using smaller dose increments (10% to 20%) across a narrower range of doses at each waveband selected on the basis of the MEDs seen 24 hours after first irradiation to establish the MED precisely. Final MEDs were assessed 24 hours later (day 3).

Power calculation

Our prestudy sample size calculation was performed to determine how many subjects were likely to be needed to detect a clinically important difference in MEDs between the *FLG* genotype groups within the 305 ± 30 nm waveband. MED data derived from testing with a geometric dose series do not follow a normal distribution, and therefore we based our sample size on the minimum difference in arithmetic means of natural log-transformed MEDs. This method was used because differences in arithmetic means of log-transformed data can be "back-transformed" to fold differences (eg, 1.8-fold), which is more understandable than the difference in log-transformed MEDs that equates to this.

MEDs for the 305 ± 5 nm waveband (representing a narrow waveband in the UVB region, the waveband of interest) from 120 healthy volunteers tested at the National Photobiology Unit were used to derive variance. These nonnormal data were log-transformed, and the numbers needed to detect a 1.5-, 1.8-, and 2-fold difference in geometric means were estimated by using Stata 12.1 software (StataCorp, College Station, Tex). Assuming that approximately 10% of the study participants would have 1 or more *FLG* loss-of-function mutations,^{E4} to obtain an 80% power with a *P* value of .05, we required at least 7 or 8 subjects with *FLG* mutations (expected within a total sample size of 70-80 subjects) to detect a difference of 1.8-fold in mean natural log-transformed MEDs at this waveband between the wild-type and *FLG*-null groups. Similarly, 55 volunteers, including 5 or 6 *FLG* mutation carriers, were needed to detect a 2-fold difference in mean natural log-transformed UVB MEDs.

Therefore the results arising from our sample size, including 71 volunteers and 10 *FLG* mutation carriers, have sufficient statistical power to effectively exclude an association with *FLG* genotype and erythema response of a 1.8-fold or greater difference at the wavebands tested.

Statistical analysis of monochromator phototesting data

When analyzing our data, we used nonparametric methods reliant on ranks, rather than absolute values, instead of parametric methods based on transformed data. This was for the practical reason that although we obtained ranks

for all MEDs, the precise values for some were unknown (greater than or less than our test dose range). Some MEDs were determined to be greater than or less than the test irradiation ranges. A small number was added to all MEDs at greater than the top dose tested for wavebands of 305 nm and longer and a small number was subtracted from MEDs of less than the lowest dose tested to allow appropriate rank-based analyses. The phototesting results were compared with *FLG* genotype status (*FLG* wild-type or *FLG* mutant) by using the Mann-Whitney *U* test to analyze these nonparametric data to test the null hypothesis that there was no association of MEDs with genotype. Corresponding CIs around medians were derived by using the methods of Altman and Gardner.^{E5} We took a *P* value of .05 or less to be significant.

REFERENCES

- E1. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. *Arch Dermatol* 1988;124:869-71.
- E2. MacKenzie LA, Frain-Bell W. The construction and development of a grating monochromator and its application to the study of the reaction of the skin to light. *Br J Dermatol* 1973;89:251-64.
- E3. Moseley H, Naasan H, Dawe RS, Woods J, Ferguson J. Population reference intervals for minimal erythema doses in monochromator phototesting. *Photodermatol Photoimmunol Photomed* 2009;25:8-11.
- E4. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. *N Engl J Med* 2011;365:1315-27.
- E5. Campbell MJ, Gardner MJ. Calculating confidence intervals for some non-parametric analyses. *Br Med J (Clin Res Ed)* 1988;296:1454-6.
- E6. Smith FJ, Irvine AD, Terron-Kwiatkowski A, Sandilands A, Campbell LE, Zhao Y, et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. *Nat Genet* 2006;38:337-42.
- E7. Brown SJ, Kroboth K, Sandilands A, Campbell LE, Pohler E, Kezic S, et al. Intragenic copy number variation within filaggrin contributes to the risk of atopic dermatitis with a dose-dependent effect. *J Invest Dermatol* 2012;132:98-104.
- E8. Kezic S, Kemperman PM, Koster ES, de Jongh CM, Thio HB, Campbell LE, et al. Loss-of-function mutations in the filaggrin gene lead to reduced level of natural moisturizing factor in the stratum corneum. *J Invest Dermatol* 2008;128:2117-9.
- E9. Kim BE, Howell MD, Guttman-Yassky E, Gilleaudeau PM, Cardinale IR, Boguniewicz M, et al. TNF-alpha downregulates filaggrin and loricrin through c-Jun N-terminal kinase: role for TNF-alpha antagonists to improve skin barrier. *J Invest Dermatol* 2011;131:1272-9.
- E10. Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, DeBenedetto A, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. *J Allergy Clin Immunol* 2007;120:150-5.
- E11. Denecker G, Hoste E, Gilbert B, Hochepeid T, Ovaere P, Lippens S, et al. Caspase-14 protects against epidermal UVB photodamage and water loss. *Nat Cell Biol* 2007;9:666-74.
- E12. Lynley AM, Dale BA. The characterization of human epidermal filaggrin. A histidine-rich, keratin filament-aggregating protein. *Biochim Biophys Acta* 1983;744:28-35.
- E13. Brown SJ, McLean WH. One remarkable molecule: filaggrin. *J Invest Dermatol* 2012;132:751-62.
- E14. Eckhart L, Schmidt M, Mildner M, Mlitz V, Abtin A, Ballaun C, et al. Histidase expression in human epidermal keratinocytes: regulation by differentiation status and all-trans retinoic acid. *J Dermatol Sci* 2008;50:209-15.
- E15. McLoone P, Simics E, Barton A, Norval M, Gibbs NK. An action spectrum for the production of cis-urocanic acid in human skin in vivo. *J Invest Dermatol* 2005;124:1071-4.
- E16. Gilmour JW, Vestey JP, George S, Norval M. Effect of phototherapy and urocanic acid isomers on natural killer cell function. *J Invest Dermatol* 1993;101:169-74.
- E17. Walterscheid JP, Nghiem DX, Kazimi N, Nutt LK, McConkey DJ, Norval M, et al. Cis-urocanic acid, a sunlight-induced immunosuppressive factor, activates immune suppression via the 5-HT2A receptor. *Proc Natl Acad Sci U S A* 2006;103:17420-5.
- E18. Elias PM, Choi EH. Interactions among stratum corneum defensive functions. *Exp Dermatol* 2005;14:719-26.
- E19. Finlay-Jones JJ, Hart PH. Photoprotection: sunscreens and the immunomodulatory effects of UV irradiation. *Mutat Res* 1998;422:155-9.
- E20. Noonan FP, De Fabo EC. Immunosuppression by ultraviolet B radiation: initiation by urocanic acid. *Immunol Today* 1992;13:250-4.




FIG E1. Diagrammatic summary of factors affecting the profilaggrin-*cis*-UCA pathway. Previous studies have demonstrated the effects of variation within *FLG*^{E6-E8} and levels of T_H2 cytokines^{E9,E10} on filaggrin expression. The role of caspase-14 in profilaggrin processing has been illustrated in mice.^{E11} Filaggrin is degraded to release a pool of amino acids rich in histidine^{E12} in the stratum corneum, contributing to barrier function through hydration and acidification.^{E13} The conversion of histidine to *trans*-UCA is catalyzed by histidase,^{E14} and the *trans*-isomer is converted to *cis*-UCA by UVB.^{E15} UVB absorption might contribute to cutaneous photoprotection, and *cis*-UCA might have additional immunomodulatory effects.^{E16-E20}

TABLE E1. Results of monochromator phototesting of 71 healthy volunteers stratified according to *FLG* genotype

	295 ± 5 nm	300 ± 5 nm	305 ± 5 nm	335 ± 30 nm	365 ± 30 nm	400 ± 30 nm	430 ± 30 nm
Waveband	Median MED (mJ/cm²)						
<i>FLG</i> wild-type subjects	10.0 (n = 53)	18.0 (n = 53)	47.0 (n = 61)	5,600 (n = 61)	24,000 (n = 61)	>82,000 (n = 61)	>82,000 (n = 61)
<i>FLG</i> heterozygous subjects	8.2 (n = 8)	15.0 (n = 8)	47.0 (n = 10)	4,950 (n = 10)	20,000 (n = 10)	82,000 (n = 10)	>82,000 (n = 10)
Difference	1.8 mJ/cm ² higher in <i>FLG</i> wild-type	3.0 mJ/cm ² higher in <i>FLG</i> wild-type	No difference	650 mJ/cm ² higher in <i>FLG</i> wild-type	4,000 mJ/cm ² higher in <i>FLG</i> wild-type	Not quantifiable	Not quantifiable
95% CI for difference	-2.6 to 5.0	-3.0 to 7.0	-9.0 to 14.0	-1,200 to 2,300	-7,000 to 9,000	Not quantifiable	Not quantifiable
<i>P</i> value (Mann-Whitney <i>U</i> test)	.41	.35	.79	.62	.74	.58	.70

Some cells are “not quantifiable” because results of greater than the highest test dose were recorded.